Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

David B. Page(Providence Portland Medical Center), Sylvia Adams(NYU Langone Health), Alexandra Thomas(Cliniques Universitaires Saint-Luc), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Kevin Kalinsky(Emory University), Benjamin G. Vincent(University of North Carolina at Chapel Hill), Margaret E. Gatti‐Mays(National Cancer Institute), Elizabeth A. Mittendorf(Beth Israel Deaconess Medical Center), Mary L. Disis(University of Washington), Julia White(The Ohio State University Wexner Medical Center), Steven J. Chmura(University of Chicago), Mei‐Yin C. Polley(Mayo Clinic in Arizona), David W. Cescon(Princess Margaret Hospital), Harry D. Bear(Virginia Commonwealth University), James L. Gulley(National Cancer Institute), Erin F. Cobain(University of Michigan), Sofia R. Gameiro(National Institutes of Health), Joseph A. Sparano(Tisch Cancer Institute), Justin M. Balko(Vanderbilt University Medical Center), Rita Nanda(University of Chicago), Sangeetha Prabhakaran(University of New Mexico), Heather L. McArthur(Southwestern Medical Center)
npj Breast Cancer
October 8, 2019
10.1038/s41523-019-0130-x
Cited by 86

Related Papers

Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Glypican-1 identifies cancer exosomes and detects early pancreatic cancer
|Nature|2015|2.9k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k